Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The US Food and Drug Administration has approved Eli Lilly's NYSE:LLY once-weekly basal insulin, Onswik, for adults with type 2 diabetes, the drugmaker said on Thursday, offering patients an alternative to daily long-acting insulin injections.Here are some details
Sept 24 (Reuters) — Eli Lilly and Company: U.s. Food And Drug Administration (Fda) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-gobe), A Once-weekly Basal Insulin Injection Treatment For Adults Living With Type 2 Diabetes Eli Lilly - Onswik Kwikpen To Be Available In U.s. In 500 Units/ml And 1,000 Units/ml Concentra
Onswik is designed to reduce injections by over 300 per year versus once-daily basal insulin1,2With Onswik, Lilly's type 2 diabetes portfolio expands to include a once-weekly basal insulin, alongside existing treatment options across insulins, incretins, oral and injectable medicationsINDIANAPOLIS…
LLY - U.S. Food and Drug Administration ( FDA ) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes